TIGECYCLINE 50mg. IP

A glycylcycline antibacterial agent for the treatment of patients with serious bacterial infections. (Alison K Meagher, 2005) Demonstrates efficacy against many isolates commonly linked to complicated skin and skin structure infections including Staphylococcus aureus, Streptococcus pyogenes, Escherichia coli, Streptococcus agalactiae, and Enterococcus faecalis. (Johannes Breedt, 2005) A promising agent that is effective against a wide spectrum of gram-positive and gram-negative bacteria, including strains resistant to other antimicrobials. (C. Betriu, 2004) A valuable therapeutic option in the treatment of complicated skin and skin structure infections. (Grolman, 2007) A safe and effective agent in hospitalized patients with serious infection caused by methicillin-resistant Staphylococcus aureus. (I Florescu & Group, 2008) An appropriate alternative to beta-lactams and fluoroquinolones for the initial empiric treatment of serious bacterial infections. (Fraise, 2006) A valuable addition to the armamentarium to treat the most resistant pathogens. (Scheinfeld, 2005) Offers an appropriate antibiotic option for hospitalized patients with mild to moderate community-acquired pneumonia. (Cilli, 2013) Displays improved activity against Streptococcus species, including penicillin-susceptible, penicillin-intermediate, and penicillin-resistant strains of Streptococcus pneumoniae. (Nickie D. Greer, 2006) Exhibits strong activity against resistant pathogens, i.e., vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, and penicillin-resistant Streptococcus pneumoniae. (Gopal Muralidharan, 2005) More effective agent than other tetracyclines against anaerobic organisms such as Bacteroides fragilis, Peptostreptococcus species, and Propionibacterium acnes. (Nickie D. Greer, 2006) A suitable therapeutic choice for complicated infections in severely ill patients with a high likelihood of multidrug-resistant bacteria. (W R Heizmann, 2015)